EUROBIO-SCIENTIFIC (ALERS.PA) Fundamental Analysis & Valuation

EPA:ALERS • FR0013240934

Current stock price

22.2 EUR
+1.25 (+5.97%)
Last:

This ALERS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. ALERS.PA Profitability Analysis

1.1 Basic Checks

  • ALERS had positive earnings in the past year.
  • ALERS had a positive operating cash flow in the past year.
  • In the past 5 years ALERS has always been profitable.
  • ALERS had a positive operating cash flow in each of the past 5 years.
ALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

1.2 Ratios

  • ALERS's Return On Assets of 0.91% is fine compared to the rest of the industry. ALERS outperforms 69.62% of its industry peers.
  • ALERS's Return On Equity of 1.30% is fine compared to the rest of the industry. ALERS outperforms 72.15% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 4.00%, ALERS is in the better half of the industry, outperforming 74.68% of the companies in the same industry.
  • ALERS had an Average Return On Invested Capital over the past 3 years of 5.13%. This is significantly below the industry average of 10.61%.
Industry RankSector Rank
ROA 0.91%
ROE 1.3%
ROIC 4%
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ALERS.PA Yearly ROA, ROE, ROICALERS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

1.3 Margins

  • ALERS's Profit Margin of 1.46% is fine compared to the rest of the industry. ALERS outperforms 70.89% of its industry peers.
  • ALERS's Profit Margin has declined in the last couple of years.
  • The Operating Margin of ALERS (7.62%) is better than 74.68% of its industry peers.
  • In the last couple of years the Operating Margin of ALERS has grown nicely.
  • ALERS's Gross Margin of 46.95% is in line compared to the rest of the industry. ALERS outperforms 45.57% of its industry peers.
  • In the last couple of years the Gross Margin of ALERS has grown nicely.
Industry RankSector Rank
OM 7.62%
PM (TTM) 1.46%
GM 46.95%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
ALERS.PA Yearly Profit, Operating, Gross MarginsALERS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ALERS.PA Health Analysis

2.1 Basic Checks

  • ALERS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ALERS remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, ALERS has less shares outstanding
  • ALERS has a better debt/assets ratio than last year.
ALERS.PA Yearly Shares OutstandingALERS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ALERS.PA Yearly Total Debt VS Total AssetsALERS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ALERS has an Altman-Z score of 3.57. This indicates that ALERS is financially healthy and has little risk of bankruptcy at the moment.
  • ALERS has a Altman-Z score of 3.57. This is in the better half of the industry: ALERS outperforms 64.56% of its industry peers.
  • The Debt to FCF ratio of ALERS is 1.48, which is an excellent value as it means it would take ALERS, only 1.48 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 1.48, ALERS belongs to the best of the industry, outperforming 91.14% of the companies in the same industry.
  • A Debt/Equity ratio of 0.07 indicates that ALERS is not too dependend on debt financing.
  • The Debt to Equity ratio of ALERS (0.07) is better than 75.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 1.48
Altman-Z 3.57
ROIC/WACC0.57
WACC6.96%
ALERS.PA Yearly LT Debt VS Equity VS FCFALERS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ALERS has a Current Ratio of 1.79. This is a normal value and indicates that ALERS is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.79, ALERS is in line with its industry, outperforming 43.04% of the companies in the same industry.
  • ALERS has a Quick Ratio of 1.25. This is a normal value and indicates that ALERS is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.25, ALERS is doing worse than 64.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.25
ALERS.PA Yearly Current Assets VS Current LiabilitesALERS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ALERS.PA Growth Analysis

3.1 Past

  • The earnings per share for ALERS have decreased strongly by -63.27% in the last year.
  • Measured over the past 5 years, ALERS shows a small growth in Earnings Per Share. The EPS has been growing by 6.82% on average per year.
  • ALERS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.47%.
  • ALERS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.21% yearly.
EPS 1Y (TTM)-63.27%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%

3.2 Future

  • ALERS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.32% yearly.
  • Based on estimates for the next years, ALERS will show a quite strong growth in Revenue. The Revenue will grow by 12.90% on average per year.
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALERS.PA Yearly Revenue VS EstimatesALERS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALERS.PA Yearly EPS VS EstimatesALERS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. ALERS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 96.52 indicates a quite expensive valuation of ALERS.
  • 74.68% of the companies in the same industry are more expensive than ALERS, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 25.61, ALERS is valued quite expensively.
  • With a Price/Forward Earnings ratio of 19.07, ALERS is valued on the expensive side.
  • ALERS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALERS is cheaper than 84.81% of the companies in the same industry.
  • ALERS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 96.52
Fwd PE 19.07
ALERS.PA Price Earnings VS Forward Price EarningsALERS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • ALERS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALERS is cheaper than 93.67% of the companies in the same industry.
  • ALERS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALERS is cheaper than 89.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.1
EV/EBITDA 7.07
ALERS.PA Per share dataALERS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • ALERS has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ALERS's earnings are expected to grow with 13.32% in the coming years.
PEG (NY)N/A
PEG (5Y)14.16
EPS Next 2Y13.32%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALERS.PA Dividend Analysis

5.1 Amount

  • ALERS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALERS.PA Fundamentals: All Metrics, Ratios and Statistics

EUROBIO-SCIENTIFIC

EPA:ALERS (3/25/2026, 7:00:00 PM)

22.2

+1.25 (+5.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-24
Earnings (Next)04-10
Inst Owners2.81%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap227.55M
Revenue(TTM)162.09M
Net Income(TTM)2.36M
Analysts84.44
Price Target30.6 (37.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 96.52
Fwd PE 19.07
P/S 1.4
P/FCF 20.1
P/OCF 15.86
P/B 1.25
P/tB 7.02
EV/EBITDA 7.07
EPS(TTM)0.23
EY1.04%
EPS(NY)1.16
Fwd EY5.24%
FCF(TTM)1.1
FCFY4.97%
OCF(TTM)1.4
OCFY6.31%
SpS15.81
BVpS17.71
TBVpS3.16
PEG (NY)N/A
PEG (5Y)14.16
Graham Number9.57
Profitability
Industry RankSector Rank
ROA 0.91%
ROE 1.3%
ROCE 6.02%
ROIC 4%
ROICexc 4.6%
ROICexgc 27.98%
OM 7.62%
PM (TTM) 1.46%
GM 46.95%
FCFM 6.98%
ROA(3y)3.54%
ROA(5y)16.42%
ROE(3y)6.48%
ROE(5y)25.15%
ROIC(3y)5.13%
ROIC(5y)17.09%
ROICexc(3y)7.07%
ROICexc(5y)35.47%
ROICexgc(3y)44.03%
ROICexgc(5y)78.19%
ROCE(3y)7.73%
ROCE(5y)25.78%
ROICexgc growth 3Y-35.35%
ROICexgc growth 5Y49.79%
ROICexc growth 3Y-58%
ROICexc growth 5Y39.27%
OM growth 3Y-38.55%
OM growth 5Y55.68%
PM growth 3Y-57.11%
PM growth 5Y-13.49%
GM growth 3Y-5.65%
GM growth 5Y7%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF 1.48
Debt/EBITDA 0.41
Cap/Depr 16.48%
Cap/Sales 1.87%
Interest Coverage 250
Cash Conversion 46.68%
Profit Quality 479.21%
Current Ratio 1.79
Quick Ratio 1.25
Altman-Z 3.57
F-Score6
WACC6.96%
ROIC/WACC0.57
Cap/Depr(3y)26.09%
Cap/Depr(5y)27.29%
Cap/Sales(3y)2.36%
Cap/Sales(5y)1.86%
Profit Quality(3y)322.49%
Profit Quality(5y)228.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-63.27%
EPS 3Y-58.79%
EPS 5Y6.82%
EPS Q2Q%-41.15%
EPS Next Y-11.36%
EPS Next 2Y13.32%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.47%
Revenue growth 3Y-5.77%
Revenue growth 5Y21.21%
Sales Q2Q%10.27%
Revenue Next Year22.03%
Revenue Next 2Y12.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.15%
EBIT growth 3Y-42.09%
EBIT growth 5Y88.7%
EBIT Next Year18.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.42%
FCF growth 3Y-40.57%
FCF growth 5Y31.67%
OCF growth 1Y-49.85%
OCF growth 3Y-36.72%
OCF growth 5Y27.33%

EUROBIO-SCIENTIFIC / ALERS.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of EUROBIO-SCIENTIFIC (ALERS.PA) stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALERS.PA.


What is the valuation status for ALERS stock?

ChartMill assigns a valuation rating of 5 / 10 to EUROBIO-SCIENTIFIC (ALERS.PA). This can be considered as Fairly Valued.


How profitable is EUROBIO-SCIENTIFIC (ALERS.PA) stock?

EUROBIO-SCIENTIFIC (ALERS.PA) has a profitability rating of 6 / 10.


What is the earnings growth outlook for EUROBIO-SCIENTIFIC?

The Earnings per Share (EPS) of EUROBIO-SCIENTIFIC (ALERS.PA) is expected to decline by -11.36% in the next year.